Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in China

ABSTRACT Background Enfortumab vedotin, a fully human monoclonal antibody–drug conjugate (ADC) directed to Nectin‐4, prolonged overall survival (OS) versus standard chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma (mUC) previously receiving a progr...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Cancer Medicine
المؤلفون الرئيسيون:	Siming Li, Yanxia Shi, Haiying Dong, Hongqian Guo, Yu Xie, Zhongquan Sun, Xiaoping Zhang, Eric Kim, Jun Zhang, Yue Li, Chenming Xu, Haishan Kadeerbai, Sue Lee, Seema Gorla, Jun Guo, Xinan Sheng
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Wiley 2024-11-01
الموضوعات:	antibody–drug conjugates efficacy monomethyl auristatin E safety urothelial carcinoma
الوصول للمادة أونلاين:	https://doi.org/10.1002/cam4.70368